Skip to main content
Photo of  John Morris, MD

John Morris, MD

Professor of Medicine, Co-Director, Comprehensive Lung Cancer Center, Associate Director, UCCI Translational Research and Director, Experimental Therapeutics

Clinical Interest

Medical Oncology
Hematology and Oncology

Research Interests

Lung, translational research, Phase I and II clinical trials, experimental therapeutics, immune therapy strategies, Hematology Oncology

Specialties

Internal Medicine
Medical Oncology

Education/Credentials
  • Medical Degree: Upstate Medical Center College of Medicine
  • Internship: Mount Sinai Hospital
  • Residency: Mount Sinai Hospital
  • Fellowship: Mount Sinai Hospital
  • Fellowship : Mount Sinai Hospital
  • Post-Doctoral Fellowship: National Institutes of Health
  • Bachelor's Degree: City University of New York
Board Certifications & Licenses
    American Board of Internal Medicine (Certification Date: 09/11/1985)
    American Board of Internal Medicine (Medical Oncology) (Certification Date: 11/07/1989)
Contact Information
  • Vontz Center for Molecular Studies
  • 3125 Eden Avenue
  • ML 0562
  • Cincinnati, Ohio 45267
  • Office 513-558-2158
  • Fax 513-558-2124
  • Email john.morris2@uc.edu
  • UC Institute Member Seal

Peer Reviewed Publications

Bouvet, Michael; Reid, Tony R; Larson, Chris; Oronsky, Bryan; Carter, Corey; Morris, John C 2019. Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. Oxford medical case reports, 2019 11, 461-463

Rahouma, Mohamed; Baudo, Massimo; Yahia, Maha; Kamel, Mohamed; Gray, Katherine D; Elmously, Adham; Ghaly, Galal; Eldessouki, Ihab; Abouarab, Ahmed; Cheriat, Ali N; Karim, Naglaa Abdel; Mohamed, Abdelrahman; Morris, John; Gaudino, Mario 2019. Pneumonitis as a complication of immune system targeting drugs?-a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Journal of thoracic disease, 11 2, 521-534

Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Morris, John C; Abdel Karim, Nagla 2018. Small or Non-Small Cell Lung Cancer Based Therapy for Treatment of Large Cell Neuroendocrine Cancer of The Lung? University of Cincinnati Experience. Journal of oncology, 2018 , 9761826

Karim, Nagla Abdel; Schuster, James; Eldessouki, Ihab; Gaber, Ola; Namad, Tariq; Wang, Jiang; Xie, Changchun; Morris, John C 2018. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience. Oncotarget, 9 3, 4102-4108

Rahouma, Mohamed; Kamel, Mohamed; Abouarab, Ahmed; Eldessouki, Ihab; Nasar, Abu; Harrison, Sebron; Lee, Benjamin; Shostak, Eugene; Morris, John; Stiles, Brendon; Altorki, Nasser K; Port, Jeffrey L 2018. Lung cancer patients have the highest malignancy-associated suicide rate in USA: a population-based analysis. Ecancermedicalscience, 12 , 859

Wise-Draper, Trisha; Sendilnathan, Arun; Palackdharry, Sarah; Pease, Nicholas; Qualtieri, Julianne; Butler, Randall; Sadraei, Nooshin Hashemi; Morris, John C; Patil, Yash; Wilson, Keith; Mark, Jonathan; Casper, Keith; Takiar, Vinita; Lane, Adam; Privette Vinnedge, Lisa 2018. Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case-Control Study of Patients with Head and Neck Squamous Cell Carcinoma. Translational oncology, 11 1, 168-174

Haugen, Bryan R; Sawka, Anna M; Alexander, Erik K; Bible, Keith C; Caturegli, Patrizio; Doherty, Gerard M; Mandel, Susan J; Morris, John C; Nassar, Aziza; Pacini, Furio; Schlumberger, Martin; Schuff, Kathryn; Sherman, Steven I; Somerset, Hilary; Sosa, Julie Ann; Steward, David L; Wartofsky, Leonard; Williams, Michelle D 2017. American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invasion to Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features. Thyroid : official journal of the American Thyroid Association, 27 4, 481-483

Agarwal, Rishi; Wang, Jiang; Wilson, Keith; Barrett, William; Morris, John C 2016. Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 14 10, 1203-1207

Ramlogan-Steel, Charmaine A; Steel, Jason C; Morris, John C 2014. Lung cancer vaccines: current status and future prospects. Translational lung cancer research, 3 1, 46-52

Alsidawi, S; Morris, J C; Wikenheiser-Brokamp, K A; Starnes, S L; Karim, N A 2013. Mucoepidermoid carcinoma of the lung: a case report and literature review. Case reports in oncological medicine, 2013 , 625243

Starnes, Sandra L; Pathrose, Peterson; Wang, Jiang; Succop, Paul; Morris, John C; Bridges, James; Kupert, Elena Y; Anderson, Marshall 2012. Clinical and molecular predictors of recurrence in stage I non-small cell lung cancer. The Annals of thoracic surgery, 93 5, 1606-12

Chen J.;Petrus M.;Bryant B.;Nguyen V.;Goldman C.;Bamford R.;Morris J.;Janik J.;Waldmann T. 12-23-2010. Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic ad Blood, 116 26, 5948-5956

Janik J.;Morris J. 12-17-2009. Survivin(g) adult T-cell leukemia/lymphoma ONCOLOGY, 23 14,

Yu P.;Steel J.;Zhang M.;Morris J.;Waldmann T. 12-15-2010. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity m Clinical Cancer Research, 16 24, 6019-6028

Steel J.C.;Morrison B.J.;Morris J.C. 12-07-2012. Monoclonal antibodies for the treatment of cancer Principles of Molecular Diagnostics and Personalized Cancer Medicine, , 580-593

Steel J.;Morrison B.;Mannan P.;Abu-Asab M.;Wildner O.;Miles B.;Yim K.;Ramanan V.;Prince G.;Morris J. 12-05-2007. Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncoly Virology, 369 1, 131-142

Komiya T.;Blumenthal G.M.;DeChowdhury R.;Fioravanti S.;Ballas M.S.;Morris J.;Hornyak T.J.;Wank S.;Hewitt S.M.;Morrow B.;Memmott R.M.;Rajan A.;Dennis P.A. 12-01-2019. A Pilot Study of Sirolimus in Subjects with Cowden Syndrome or Other Syndromes Characterized by Germ Oncologist, 24 12, 1510-e1265

Berzofsky J.;Terabe M.;Trepel J.;Pastan I.;Stroncek D.;Morris J.;Wood L. 12-01-2018. Cancer vaccine strategies: translation from mice to human clinical trials Cancer Immunology, Immunotherapy, 67 12, 1863-1869

Berkowitz J.;Janik J.;Stewart D.;Jaffe E.;Stetler-Stevenson M.;Shih J.;Fleisher T.;Turner M.;Urquhart N.;Wharfe G.;Figg W.;Peer C.;Goldman C.;Waldmann T.;Morris J. 12-01-2014. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with a Clinical Immunology, 155 2, 176-187

Morris J.;Waldmann T. 12-01-2009. Antibody-based therapy of leukaemia Expert Reviews in Molecular Medicine, 11 ,

Morrison B.J.;Steel J.C.;Gregory M.;Morris J.C.;Malyguine A.M. 12-01-2009. Genetically modified dendritic cells in cancer immunotherapy Dendritic Cells in Cancer, , 347-363

Sharp H.;Morris J.;Van Waes C.;Gius D.;Cooley-Zgela T.;Singh A. 12-01-2008. High incidence of oral dysesthesias on a trial of gefitinib, paclitaxel, and concurrent external bea American Journal of Clinical Oncology: Cancer Clinical Trials, 31 6, 557-560

Alesci S.;Abu-Asab M.;Perera S.;Tsokos M.;Morris J.;Pacak K. 12-01-2007. Mitochondrial localization of human recombinant adenovirus: From evolution to gene therapy NeuroImmunoModulation, 14 5, 221-223

Van Waes C.;Chang A.A.;Lebowitz P.F.;Druzgal C.H.;Chen Z.;Elsayed Y.A.;Sunwoo J.B.;Rudy S.F.;Morris J.C.;Mitchell J.B.;Camphausen K.;Gius D.;Adams J.;Sausville E.A.;Conley B.A. 12-01-2005. Inhibition of nuclear factor-?B and target genes during combined therapy with proteasome inhibitor b International Journal of Radiation Oncology Biology Physics, 63 5, 1400-1412

Lei J.Y.;Wang Y.;Jaffe E.S.;Turner M.L.;Raffeld M.;Sorbara L.;Morris J.;Holland S.M.;Duray P.H. 12-01-2000. Microcystic adnexal carcinoma associated with primary immunodeficiency, recurrent diffuse herpes sim American Journal of Dermatopathology, 22 6, 524-529

Morris J.;Waldmann T. 11-20-2000. Advances in interleukin 2 receptor targeted treatment Annals of the Rheumatic Diseases, 59 SUPPL. 1,

Pise-Masison C.;Radonovich M.;Dohoney K.;Morris J.;O'Mahony D.;Lee M.;Trepel J.;Waldmann T.;Janik J.;Brady J. 11-17-2009. Gene expression profiling of ATL patients: Compilation of disease-related genes and evidence for TCF Blood, 113 17, 4016-4026

Janik J.;Morris J.;Pittaluga S.;McDonald K.;Raffeld M.;Jaffe E.;Grant N.;Gutierrez M.;Waldmann T.;Wilson W. 11-15-2004. Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma Blood, 104 10, 3355-3357

Morrison B.;Steel J.;Morris J. 11-13-2012. Sphere Culture of Murine Lung Cancer Cell Lines Are Enriched with Cancer Initiating Cells PLoS ONE, 7 11,

Ferris R.L.;Saba N.F.;Gitlitz B.J.;Haddad R.;Sukari A.;Neupane P.;Morris J.C.;Misiukiewicz K.;Bauman J.E.;Fenton M.;Jimeno A.;Adkins D.R.;Schneider C.J.;Sacco A.G.;Shirai K.;Bowles D.W.;Gibson M.;Nwizu T.;Gottardo R.;Manjarrez K.L.;Dietsch G.N.;Kyle Bryan J.;Hershberg R.M.;Cohen E.E.W. 11-01-2018. Effect of adding motolimod to standard combination chemotherapy and cetuximab treatment of patients JAMA Oncology, 4 11, 1583-1588

Shurin M.;Gregory M.;Morris J.;Malyguine A. 11-01-2010. Genetically modified dendritic cells in cancer immunotherapy: A better tomorrow? Expert Opinion on Biological Therapy, 10 11, 1539-1553

Eisenhofer G.;Huynh T.;Elkahloun A.;Morris J.;Bratslavsky G.;Linehan W.;Zhuang Z.;Balgley B.;Lee C.;Mannelli M.;Lenders J.;Bornstein S.;Pacak K. 11-01-2008. Differential expression of the regulated catecholamine secretory pathway in different hereditary for American Journal of Physiology - Endocrinology and Metabolism, 295 5,

Ohta S.;Lai E.W.;Morris J.C.;Bakan D.A.;Klaunberg B.;Cleary S.;Powers J.F.;Tischler A.S.;Abu-Asab M.;Schimel D.;Pacak K. 11-01-2006. MicroCT for high-resolution imaging of ectopic pheochromocytoma tumors in the liver of nude mice International Journal of Cancer, 119 9, 2236-2241

Sakai Y.;Morrison B.;Burke J.;Park J.;Terabe M.;Janik J.;Forni G.;Berzofsky J.;Morris J. 11-01-2004. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents dev Cancer Research, 64 21, 8022-8028

Wildner O.;Blaese R.;Morris J. 11-01-1999. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase Human Gene Therapy, 10 16, 2679-2687

Vaishampayan U.;Schöffski P.;Ravaud A.;Borel C.;Peguero J.;Chaves J.;Morris J.C.;Kotecki N.;Smakal M.;Zhou D.;Guenther S.;Bajars M.;Gulley J.L. 10-24-2019. Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell c Journal for ImmunoTherapy of Cancer, 7 1,

Janik J.E.;Morris J.C.;O'Mahony D.;Pittaluga S.;Jaffe E.S.;Redon C.E.;Bonner W.M.;Brechbiel M.W.;Paik C.H.;Whatley M.;Chen C.;Lee J.H.;Fleisher T.A.;Brown M.;White J.D.;Stewart D.M.;Fioravanti S.;Lee C.C.;Goldman C.K.;Bryant B.R.;Junghans R.P.;Carrasquillo J.A.;Worthy T.;Corcoran E.;Conlon K.C.;Waldmann T.A. 10-20-2015. <sup>90</sup>Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% o Proceedings of the National Academy of Sciences of the United States of America, 112 42, 13045-13050

Savona M.;Kolibaba K.;Conkling P.;Kingsley E.;Becerra C.;Morris J.;Rifkin R.;Laille E.;Kellerman A.;Ukrainskyj S.;Dong Q.;Skikne B. 10-01-2018. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies American Journal of Hematology, 93 10, 1199-1206

Bryan J.K.; Cohen E.; Dietsch G.N.; Ferris R.L.; Gitlitz B.; Haddad R.; Hershberg R.M.; Manjarrez K.L.; Misiukiewicz K.; Morris J.C.; Neupane P.; Saba N.F.; Sukari A. 10-01-2016. immunotherapy of cancer Active8: A randomized, double-blind, placebo-controlled study of chemotherap Annals of Oncology, 27 , vi573

Janik J.;O'Mahony D.;Waldmann T.;Morris J. 09-09-2009. Monoclonal antibody therapy of T cell lymphoma: Single agent trials of anti-CD2 (Siplizumab) and ant Haematologica Meeting Reports, 3 1, 61-68

Morrison B.;Morris J.;Steel J. 09-01-2013. Lung cancer-initiating cells: A novel target for cancer therapy Targeted Oncology, 8 3, 159-172

Druzgal C.;Chen Z.;Yeh N.;Thomas G.;Ondrey F.;Duffey D.;Vilela R.;Ende K.;McCullagh L.;Rudy S.;Muir C.;Herscher L.;Morris J.;Albert P.;Van Waes C. 09-01-2005. A pilot study of longitudinal serum cytokine and angiogenesis factor levels as markers of therapeuti Head and Neck, 27 9, 771-784

Wildner O.;Morris J. 08-31-2000. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex vi Cancer Research, 60 15, 4167-4174

Simone C.B.;Morris J.C.;Stewart D.M.;Urquhart N.E.;Janik J.E.;Kreitman R.J.;Lita E.;Conlon K.;Wharfe G.;Waldmann T.A.;Kaushal A. 08-30-2012. Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lympho Blood, 120 9, 1816-1819

Rahouma M.;Kamel M.;Abouarab A.;Eldessouki I.;Nasar A.;Harrison S.;Lee B.;Shostak E.;Morris J.;Stiles B.;Altorki N.K.;Port J.L. 08-16-2018. Lung cancer patients have the highest malignancy-associated suicide rate in USA: A population-based ecancermedicalscience, 12 ,

Haque S.;Morris J. 08-03-2017. Transforming growth factor-?: A therapeutic target for cancer Human Vaccines and Immunotherapeutics, 13 8, 1741-1750

Rixe O.;Puzanov I.;Lo Russo P.M.;Cohen R.B.;Morris J.C.;Olowokure O.O.;Yin J.Y.;Doroumian S.;Shen L.;Olszanski A.J. 08-01-2015. Phase i dose-escalation study of cabazitaxel administered in combination with gemcitabine in patient Anti-Cancer Drugs, 26 7, 785-792

Pang Y.;Gara S.;Achyut B.;Li Z.;Yan H.;Day C.;Weiss J.;Trinchieri G.;Morris J.;Yang L. 08-01-2013. TGF-? Signaling in myeloid cells is required for tumor metastasis Cancer Discovery, 3 8, 936-951

Larson T.;Hu M.;Janik J.;Nussenblatt R.;Morris J.;Sen H. 08-01-2012. Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia Ocular Immunology and Inflammation, 20 4, 312-314

Stewart D.;Ramanathan R.;Mahanty S.;Fedorko D.;Janik J.;Morris J. 08-01-2011. Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma Acta Haematologica, 126 2, 63-67

Alesci S.;Perera S.;Lai E.;Kukura C.;Abu-Asab M.;Tsokos M.;Morris J.;Pacak K. 08-01-2007. Adenoviral gene transfer in bovine adrenomedullary and murine pheochromocytoma cells: Potential clin Endocrinology, 148 8, 3900-3907

Berzofsky J.;Ahlers J.;Janik J.;Morris J.;Oh S.;Terabe M.;Belyakov I. 08-01-2004. Progress on new vaccine strategies against chronic viral infections Journal of Clinical Investigation, 114 4, 450-462

Morgensztern D.;Rose M.;Waqar S.N.;Morris J.;Ma P.C.;Reid T.;Brzezniak C.E.;Zeman K.G.;Padmanabhan A.;Hirth J.A.;I. Spira A.;Trepel J.B.;Padda S.K. 07-30-2019. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung canc British Journal of Cancer, 121 3, 211-217

Waldmann T.A.;Conlon K.C.;Stewart D.M.;Worthy T.Y.A.;Janik J.E.;Fleisher T.A.;Albert P.S.;Figg W.D.;Spencer S.D.;Raffeld M.;Decker J.R.;Goldman C.K.;Bryant B.R.;Petrus M.N.;Creekmore S.P.;Morris J.C. 07-17-2013. Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T Blood, 121 3, 476-484

Citrin D.;Mansueti J.;Likhacheva A.;Sciuto L.;Albert P.;Rudy S.;Cooley-Zgela T.;Cotrim A.;Solomon B.;Colevas A.;Russo A.;Morris J.;Herscher L.;Smith S.;Van Waes C. 07-15-2009. Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiotherapy for Locally Advanced Head- International Journal of Radiation Oncology Biology Physics, 74 4, 1040-1046

Venkataraman G.;Berkowitz J.;Morris J.;Janik J.;Raffeld M.;Pittaluga S. 07-01-2011. Adult T-cell leukemia/lymphoma with Epstein-Barr virus-positive Hodgkin-like cells Human Pathology, 42 7, 1042-1046

Zandvakili I.;Lin Y.;Morris J.;Zheng Y. 06-08-2017. Rho GTPases: Anti-or pro-neoplastic targets? Oncogene, 36 23, 3213-3222

Wise-Draper T.;Moorthy G.;Salkeni M.;Karim N.;Thomas H.;Mercer C.;Beg M.;O’Gara S.;Olowokure O.;Fathallah H.;Kozma S.;Thomas G.;Rixe O.;Desai P.;Morris J. 06-01-2017. A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Pat Targeted Oncology, 12 3, 323-332

Tembhare P.;Yuan C.;Xi L.;Morris J.;Liewehr D.;Venzon D.;Janik J.;Raffeld M.;Stetler-Stevenson M. 06-01-2011. Flow cytometric immunophenotypic assessment of T-cell clonality by V <inf>?</inf> repert American Journal of Clinical Pathology, 135 6, 890-900

Van Waes C.;Allen C.;Citrin D.;Gius D.;Colevas A.;Harold N.;Rudy S.;Nottingham L.;Muir C.;Chen Z.;Singh A.;Dancey J.;Morris J. 06-01-2010. Molecular and Clinical Responses in a Pilot Study of Gefitinib With Paclitaxel and Radiation in Loca International Journal of Radiation Oncology Biology Physics, 77 2, 447-454

Morris J.;Janik J. 06-01-2007. Therapeutic immunotoxins for lymphoid malignancies: The end of the beginning Leukemia and Lymphoma, 48 6, 1067-1069

Wolkersdörfer G.W.;Morris J.C.;Ehninger G.;Ramsey W.J. 06-01-2004. Trans-complementing adenoviral vectors for oncolytic therapy of malignant melanoma Journal of Gene Medicine, 6 6, 652-662

Morris J. 06-01-2003. Cancer gene therapy: Lessons learned from experiences with chemotherapy Molecular Therapy, 7 6, 717-719

Waldmann T.;Morris J. 05-29-2006. Development of Antibodies and Chimeric Molecules for Cancer Immunotherapy Advances in Immunology, 90 , 83-131

Rahouma M.;Karim N.A.;Baudo M.;Yahia M.;Kamel M.;Eldessouki I.;Abouarab A.;Saad I.;Elmously A.;Gray K.D.;Ghaly G.;Gaber O.;Kamal M.;A Hassan A.;Rahouma M.;D'Ascenzo F.;Morris J.;Mohamed A.;Girardi L.;Gaudino M. 05-15-2019. Cardiotoxicity with immune system targeting drugs: A meta-analysis of anti-PD/PD-L1 immunotherapy ra Immunotherapy, 11 8, 725-735

Chen J.;Petrus M.;Bryant B.R.;Nguyen V.P.;Stamer M.;Goldman C.K.;Bamford R.;Morris J.C.;Janik J.E.;Waldmann T.A. 05-15-2008. Induction of the IL-9 gene by HTLV-I Tax stimulates the spontaneous proliferation of primary adult T Blood, 111 10, 5163-5172

Morrison B.;Steel J.;Morris J. 05-01-2013. Immunotherapy in lung cancer: The potential of cancer stem cells in future therapies Future Oncology, 9 5, 623-625

Moriyama B.;Henning S.;Childs R.;Holland S.;Anderson V.;Morris J.;Wilson W.;Drusano G.;Walsh T. 05-01-2010. High-dose continuous infusion ?-lactam antibiotics for the treatment of resistant Pseudomonas aerugi Annals of Pharmacotherapy, 44 5, 929-935

Morrison B.;Steel J.;Morris J. 04-26-2018. Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells BMC Cancer, 18 1,

Yu P.;Steel J.;Zhang M.;Morris J.;Waitz R.;Fasso M.;Allison J.;Waldmann T. 04-17-2012. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prost Proceedings of the National Academy of Sciences of the United States of America, 109 16, 6187-6192

Kelly R.;Lopez-Chavez A.;Citrin D.;Janik J.;Morris J. 04-06-2011. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin Molecular Cancer, 10 ,

Pal S.;Forero-Torres A.;Thompson J.;Morris J.;Chhabra S.;Hoimes C.;Vogelzang N.;Boyd T.;Bergerot P.;Adashek J.;Li H.;Yu X.;Gartner E.;Carret A.;Smith D. 04-01-2019. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma Cancer, 125 7, 1124-1132

Shao H.;Yuan C.;Xi L.;Raffeld M.;Morris J.;Janik J.;Stetler-Stevenson M. 04-01-2010. Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma American Journal of Clinical Pathology, 133 4, 592-601

Jiang L.;Yuan C.;Hubacheck J.;Janik J.;Wilson W.;Morris J.;Jasper G.;Stetler-Stevenson M. 04-01-2009. Variable CD52 expression in mature T cell and NK cell malignancies: Implications for alemtuzumab the British Journal of Haematology, 145 2, 173-179

O'Mahony D.;Morris J.;Stetler-Stevenson M.;Matthews H.;Brown M.;Fleisher T.;Pittaluga S.;Raffeld M.;Albert P.;Reitsma D.;Kaucic K.;Hammershaimb L.;Waldmann T.;Janik J. 04-01-2009. EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, Clinical Cancer Research, 15 7, 2514-2522

Pernas F.G.;Allen C.T.;Winters M.E.;Yan B.;Friedman J.;Dabir B.;Saigal K.;Mundinger G.S.;Xu X.;Morris J.C.;Calvo K.R.;Van Waes C.;Chen Z. 04-01-2009. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to Clinical Cancer Research, 15 7, 2361-2372

Morris J.;Waldmann T.;Janik J. 04-01-2008. Receptor-directed therapy of T-cell leukemias and lymphomas Journal of Immunotoxicology, 5 2, 235-248

Ohta S.;Lai E.W.;Morris J.C.;Pang A.L.Y.;Watanabe M.;Yazawa H.;Zhang R.;Green J.E.;Chan W.Y.;Sirajuddin P.;Taniguchi S.;Powers J.F.;Tischler A.S.;Pacak K. 04-01-2008. Metastasis-associated gene expression profile of liver and subcutaneous lesions derived from mouse p Molecular Carcinogenesis, 47 4, 245-251

Steel J.;Cavanagh H.;Burton M.;Abu-Asab M.;Tsokos M.;Morris J.;Kalle W. 04-01-2007. Increased tumor localization and reduced immune response to adenoviral vector formulated with the li European Journal of Pharmaceutical Sciences, 30 5, 398-405

Park J.;Terabe M.;Sakai Y.;Munasinghe J.;Forni G.;Morris J.;Berzofsky J. 04-01-2005. Early role of CD4<sup>+</sup> Th1 cells and antibodies in HER-2 adenovirus vaccine prote Journal of Immunology, 174 7, 4228-4236

Lacouture M.;Morris J.;Lawrence D.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Berzofsky J.;Hsu F.;Guitart J. 03-22-2015. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming g Cancer Immunology, Immunotherapy, 64 4, 437-446

Jong M.;Terabe M.;Steel J.;Forni G.;Sakai Y.;Morris J.;Berzofsky J. 03-15-2008. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccin Cancer Research, 68 6, 1979-1987

Morris J.;Tan A.;Olencki T.;Shapiro G.;Dezube B.;Reiss M.;Hsu F.;Berzofsky J.;Lawrence D. 03-11-2014. Phase I study of GC1008 (Fresolimumab): A human anti-transforming growth factor-beta (TGF?) monoclon PLoS ONE, 9 3,

Kelly R.;Morris J. 03-01-2010. Transforming growth factor-beta: A target for cancer therapy Journal of Immunotoxicology, 7 1, 15-26

Martiniova L.;Lai E.;Elkahloun A.;Abu-Asab M.;Wickremasinghe A.;Solis D.;Perera S.;Huynh T.;Lubensky I.;Tischler A.;Kvetnansky R.;Alesci S.;Morris J.;Pacak K. 03-01-2009. Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific g Clinical and Experimental Metastasis, 26 3, 239-250

O'Mahony D.;Debnath I.;Janik J.;Aisner D.;Jaffe E.;Waldmann T.;Morris J. 03-01-2008. Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/ly Leukemia and Lymphoma, 49 3, 439-446

Burke J.;Morris J. 03-01-2007. Retroviral vectors encoding a reverse transcription-activated transgene efficiently limit expression Molecular Therapy, 15 3, 552-559

Okada T.;Caplen N.;Ramsey W.;Onodera M.;Shimazaki K.;Nomoto T.;Ajalli R.;Wildner O.;Morris J.;Kume A.;Hamada H.;Blaese R.;Ozawa K. 03-01-2004. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor ce Journal of Gene Medicine, 6 3, 288-299

Ju W.;Zhang M.;Jiang J.K.;Thomas C.J.;Oh U.;Bryant B.R.;Chen J.;Sato N.;Tagaya Y.;Morris J.C.;Janik J.E.;Jacobson S.;Waldmann T.A. 02-10-2011. CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T c Blood, 117 6, 1938-1946

Morris J.;Ramsey W.;Wildner O.;Muslow H.;Aguilar-Cordova E.;Blaese R. 02-10-2000. A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidi Human Gene Therapy, 11 3, 487-503

Sarantopoulos J.;Mita A.C.;Wade J.L.;Morris J.C.;Rixe O.;Mita M.M.;Dedieu J.F.;Wack C.;Kassalow L.;Craig Lockhart A. 02-05-2014. Phase i study of cabazitaxel plus cisplatin in patients with advanced solid tumors: Study to evaluat Cancer Chemotherapy and Pharmacology, 74 6, 1113-1124

Sarantopoulos J.;Mita A.C.;He A.;Wade J.L.;Hsueh C.T.;Morris J.C.;Lockhart A.C.;Quinn D.I.;Hwang J.;Mier J.;Zhang W.;Wack C.;Yin J.;Clot P.F.;Rixe O. 02-01-2017. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escal Cancer Chemotherapy and Pharmacology, 79 2, 339-351

Tembhare P.;Yuan C.;Morris J.;Janik J.;Filie A.;Stetler-Stevenson M. 02-01-2012. Flow cytometric immunophenotypic assessment of T-cell clonality by V <inf>?</inf> repert American Journal of Clinical Pathology, 137 2, 220-226

Martiniova L.;Perera S.M.;Brouwers F.M.;Alesci S.;Abu-Asab M.;Marvelle A.F.;Kiesewetter D.O.;Thomasson D.;Morris J.C.;Kvetnansky R.;Tischler A.S.;Reynolds J.C.;Fojo A.T.;Pacak K. 02-01-2011. Increased uptake of [<sup>123</sup>I]meta-iodobenzylguanidine, [ <sup>18</sup&g Endocrine-Related Cancer, 18 1, 143-157

Steel J.;Ramlogan C.;Yu P.;Sakai Y.;Forni G.;Waldmann T.;Morris J. 02-01-2010. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through Cancer Research, 70 3, 1072-1081

O'Mahony D.;Morris J.;Quinn C.;Gao W.;Wilson W.;Gause B.;Pittaluga S.;Neelapu S.;Brown M.;Fleisher T.;Gulley J.;Schlom J.;Nussenblatt R.;Albert P.;Davis T.;Lowy I.;Petrus M.;Waldmann T.;Janik J. 02-01-2007. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy Clinical Cancer Research, 13 3, 958-964

Wildner O.;Blaese R.;Morris J. 01-16-1999. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex viru Cancer Research, 59 2, 410-413

Gulati S.;Desai J.;Palackdharry S.M.;Morris J.C.;Zhu Z.;Jandarov R.;Riaz M.K.;Takiar V.;Mierzwa M.;Gutkind J.S.;Molinolo A.;Desai P.B.;Sadraei N.H.;Wise-Draper T.M. 01-15-2020. Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in Cancer, 126 2, 354-362

Cohen E.E.W.;Soulières D.;Le Tourneau C.;Dinis J.;Licitra L.;Ahn M.J.;Soria A.;Machiels J.P.;Mach N.;Mehra R.;Burtness B.;Zhang P.;Cheng J.;Swaby R.F.;Harrington K.J.;Acosta-Rivera M.;Adkins D.R.;Aghmesheh M.;Airoldi M.;Aleknavicius E.;Al-Farhat Y.;Algazi A.P.;Almokadem S.;Alyasova A.;Bauman J.R.;Benasso M.;Berrocal A.;Bray V.;Burtness B.A.;Caponigro F.;Castro A.;Cescon T.P.;Chan K.;Chaudhry A.;Chauffert B.;Cohen E.;Csoszi T.;De Boer J.P.;Delord J.P.;Dietz A.;Dinis J.;Dupuis C.;Digue L.;Erfan J.;Escobar Alvarez Y.;Evans M.;Fidler M.J.;Forster M.D.;Friesland S.;Ganti A.K.;Geoffrois L.;Grant C.;Gruenwald V.;Harrington K.;Hoffmann T.;Horvai G.;Inciura A.;Jang R.;Jankowska P.;Jimeno A.;Joseph M.;Juarez Ramiro A.;Karaszewska B.;Kawecki A.;Keilholz U.;Keller U.;Kim S.B.;Kocsis J.;Kotecki N.;Kozloff M.F.;Lambea J.;Landherr L.;Lantsukhay Y.;Lazarev S.A.;Lee L.W.;Lifirenko I.D.;Martincic D.;Matorin O.V.;McGrath M.;Misiukiewicz K.;Morris J.C.;Mufazalov F.F.;Niu J.;Pamoorthy Srinivasan D.;Perez Segura P.;Rauch D.;Ribeiro M.L.;Rodriguez C.;Rolland F.;Russo A.;Ruzsa A.;Sanches F.;Shin S.W.;Shtiveland M.;Soulières D.;Specenier P.;Szekanecz E.;Szota J.;van Herpen C.M.L.;Velez-Cortes H.A. 01-12-2019. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck The Lancet, 393 10167, 156-167

Morris J.;Janik J.;White J.;Fleisher T.;Brown M.;Tsudo M.;Goldman C.;Bryant B.;Petrus M.;Top L.;Lee C.;Gao W.;Waldmann T. 01-10-2006. Preclinical and phase I clinical trial of blockade of IL-15 using Mik?1 monoclonal antibody in T cel Proceedings of the National Academy of Sciences of the United States of America, 103 2, 401-406

Chen J.;Petrus M.;Bamford R.;Shih J.;Morris J.;Janik J.;Waldmann T. 01-05-2012. Increased serum soluble IL-15R? levels in T-cell large granular lymphocyte leukemia Blood, 119 1, 137-143

Abdel-Karim N.;Gaber O.;Eldessouki I.;Bahassi E.M.;Morris J. 01-01-2019. Exosomes as a surrogate marker for autophagy in peripheral blood, correlative data from phase i stud Asian Pacific Journal of Cancer Prevention, 20 12, 3789-3796

Gaber O.;Eldessouki I.;Hassan R.;Magdy M.;Morris J.;Karim N. 01-01-2019. Retrospective study of the effect of statins on the outcome of lung cancer patients, University of C Asian Pacific Journal of Cancer Prevention, 20 8, 2391-2396

Morrison B.;Abu-Asab M.;Morris J.;Steel J. 01-01-2019. Localization of human recombinant adenoviral vectors to the mitochondria following transduction of h Acta virologica, 63 1, 111-116

Rahouma M.;Baudo M.;Yahia M.;Kamel M.;Gray K.D.;Elmously A.;Ghaly G.;Eldessouki I.;Abouarab A.;Cheriat A.N.;Karim N.A.;Mohamed A.;Morris J.;Gaudino M. 01-01-2019. Pneumonitis as a complication of immune system targeting drugs?—a meta-analysis of anti-PD/PD-L1 imm Journal of Thoracic Disease, 11 2, 521-534

Eldessouki I.;Gaber O.;Namad T.;Wang J.;Morris J.;Karim N. 01-01-2018. Small or non-small cell lung cancer based therapy for treatment of large cell neuroendocrine cancer Journal of Oncology, 2018 ,

Karim N.A.;Schuster J.;Eldessouki I.;Gaber O.;Namad T.;Wang J.;Xie C.;Morris J.C. 01-01-2018. Pulmonary sarcomatoid carcinoma: University of Cincinnati experience Oncotarget, 9 3, 4102-4108

Wise-Draper T.;Sendilnathan A.;Palackdharry S.;Pease N.;Qualtieri J.;Butler R.;Sadraei N.;Morris J.;Patil Y.;Wilson K.;Mark J.;Casper K.;Takiar V.;Lane A.;Privette Vinnedge L. 01-01-2018. Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in Translational Oncology, 11 1, 168-174

Sharma K.;Janik J.E.;O'Mahony D.;Stewart D.;Pittaluga S.;Stetler-Stevenson M.;Jaffe E.S.;Raffeld M.;Fleisher T.A.;Lee C.C.;Steinberg S.M.;Waldmann T.A.;Morris J.C. 01-01-2017. Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia/l Clinical Cancer Research, 23 1, 35-42

Conlon K.C.;Lugli E.;Welles H.C.;Rosenberg S.A.;Fojo A.T.;Morris J.C.;Fleisher T.A.;Dubois S.P.;Perera L.P.;Stewart D.M.;Goldman C.K.;Bryant B.R.;Decker J.M.;Chen J.;Worthy T.A.;Figg W.D.;Peer C.J.;Sneller M.C.;Lane H.C.;Yovandich J.L.;Creekmore S.P.;Roederer M.;Waldmann T.A. 01-01-2015. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine Journal of Clinical Oncology, 33 1, 74-82

Palma N.;Morris J.C.;Ali S.M.;Ross J.S.;Pal S.K. 01-01-2015. Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating European Urology, 68 1, 168-170

Van Waes C.;Bian Y.;Allen C.;Morris J.;Chen Z. 01-01-2015. Squamous-cell carcinoma Molecular Oncology: Causes of Cancer and Targets for Treatment, , 686-692

Wang Y.;Sui Y.;Kato S.;Hogg A.E.;Steel J.C.;Morris J.C.;Berzofsky J.A. 01-01-2015. Vaginal type-II mucosa is an inductive site for primary CD8<sup>+</sup> T-cell mucosal i Nature Communications, 6 ,

Ghose A.;Morris J.C.;Breneman J.C.;Essell J.;Wang J.;Benzaquen S. 01-01-2014. Medulloblastoma in an adult with late extraneural metastases to the mediastinum Journal of Investigative Medicine High Impact Case Reports, 2 2,

Morris J.;Ramlogan-Steel C.;Yu P.;Black B.;Mannan P.;Allison J.;Waldmann T.;Steel J. 01-01-2014. Vaccination with tumor cells expressing IL-15 and IL-15R inhibits murine breast and prostate cancer Gene Therapy, 21 4, 393-401

Ramlogan-Steel C.;Steel J.;Morris J. 01-01-2014. Lung cancer vaccines: Current status and future prospects Translational Lung Cancer Research, 3 1, 46-52

Chen J.;Pise-Masison C.;Shih J.;Morris J.;Janik J.;Conlon K.;Keating A.;Waldmann T. 01-01-2013. Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 Blood, 121 11, 2029-2037

Steel J.;Di Pasquale G.;Ramlogan C.;Patel V.;Chiorini J.;Morris J. 01-01-2013. Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth Molecular Therapy, 21 3, 680-687

Starnes S.;Pathrose P.;Wang J.;Succop P.;Morris J.;Bridges J.;Kupert E.;Anderson M. 01-01-2012. Clinical and molecular predictors of recurrence in stage i non-small cell lung cancer Annals of Thoracic Surgery, 93 5, 1606-1612

Steel J.;Waldmann T.;Morris J. 01-01-2012. Interleukin-15 biology and its therapeutic implications in cancer Trends in Pharmacological Sciences, 33 1, 35-41

Vinogradova Y.;Kaplanskaya I.;Samoilova R.;Vorobiev I.;Zingerman B.;Sidorova Y.;Shklovskiy-Kordi N.;Aitova L.;Maryin D.;Morris J.;Varticovski L.;Vorobiev A. 01-01-2012. Clinicopathological features and outcomes of T- and NK-cell lymphomas in european Russia Clinical Medicine Insights: Blood Disorders, 5 , 1-13

Lai E.;Joshi B.;Martiniova L.;Dogra R.;Fujisawa T.;Leland P.;De Krijger R.;Lubensky I.;Elkahloun A.;Morris J.;Puri R.;Pacak K. 01-01-2009. Overexpression of interleukin-13 receptor-?2 in neuroendocrine malignant pheochromocytoma: A novel t Journal of Clinical Endocrinology and Metabolism, 94 8, 2952-2957

Berzofsky J.;Terabe M.;Oh S.;Belyakov I.;Ahlers J.;Janik J.;Morris J. 01-01-2004. Progress on new vaccine strategies for the immunotherapy and prevention of cancer Journal of Clinical Investigation, 113 11, 1515-1525

Lee S.S.;Robinson M.R.;Morris J.C.;Mirtsching B.C.;Shen D.F.;Chan C.C. 01-01-2004. Conjunctival involvement with T-cell prolymphocytic leukemia: Report of a case and review of the lit Survey of Ophthalmology, 49 5, 525-536

Wildner O.;Morris J. 01-01-2002. Subcutaneous administration of a replication-competent adenovirus expressing HSV-tk to cotton rats: Human Gene Therapy, 13 1, 101-112

Morris J.;Wildner O. 01-01-2000. Therapy of Head and Neck Squamous Cell Carcinoma with an Oncolytic Adenovirus Expressing HSV-tk Molecular Therapy, 1 1, 56-62

Wildner O.;Morris J. 01-01-2000. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses Journal of Gene Medicine, 2 5, 353-360

Wildner O.;Morris J.;Vahanian N.;Ford H.;Ramsey W.;Blaese R. 01-01-1999. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of Gene Therapy, 6 1, 57-62

Ghose, Abhimanyu; Morris, John C; Breneman, John C; Essell, James; Wang, Jiang; Benzaquen, Sadia . Medulloblastoma in an Adult With Late Extraneural Metastases to the Mediastinum. Journal of investigative medicine high impact case reports, 2 2, 2324709614532798